Sinopec Capital and Meinian Onehealth both invested in the biotech research product maker as it prepares for an initial public offering.

Existing backer Gilead Sciences returned for a series B round that boosted the kidney disease therapy developer's total funding to $160m.

Index Ventures participated in a round that valued the WarnerMedia and Tencent-backed communication platform developer at $3.5bn.

Tencent has reportedly committed to a series C round set to triple grocery delivery platform Xingsheng Youxuan's valuation to $3bn.

The pharmaceutical company co-led a series C round for AAV gene therapy developer Freeline that took its total funding to $275m.

Syncona supplied a third of the investment and retains a majority stake in Freeline, which is based on research at UCL.

The health insurance provider pushed its overall funding past $1.5bn in a late-stage round that included long-term investor Alphabet.

The endpoint management software provider has secured roughly $120m from strategic partner Salesforce, bumping its valuation up from $6.5bn to $9bn.

Novartis and Transposagen-backed gene and cell therapy developer Poseida Therapeutics closed the series D round two days after filing to go public.

The short-term apartment provider raised the funding at a $1.3bn valuation and is seeking another $30m to close the round at $200m.